abstract: Obesity independently increases the risk of @entity1151 ( @entity1151 ). We compare a superobese population (body mass index [BMI] > 55 kg/m(2)) undergoing open gastric bypasses (OGBs) with a similarly matched group of laparoscopic gastric bypasses (LGB) to see if the incidence of @entity1151 differs. We included all @entity1 undergoing OGB (n = 193, average BMI = 51 kg/m(2)) at our institution by a single surgeon between July 1999 and April 2001. Thirty-one @entity1 were superobese (BMI > 55 kg/m(2)). LGB was started at our institution in April 2001. Since that time 213 @entity1 (average BMI = 52 kg/m(2)) have undergone the procedure. One hundred and nine @entity1 were superobese. Pre- and postoperative prophylaxis included sequential compression stockings and subcutaneous heparin. Postoperatively, @entity1 who developed signs of @entity519 , @entity7405 , or @entity591 underwent a chest X-ray and spiral computed tomography. In addition, all @entity1 who expired in the 30-day postoperative period underwent postmortem examination. Data were analyzed using the chi-squared test. In the OGB group, four @entity1 (2.1%) developed @entity1151 . All occurred in superobese @entity1 with a BMI > 55 kg/m(2). Three were fatal PEs and one was nonfatal. None of these @entity1 had a prior history of @entity1150 , @entity1151 , @entity66 , or @entity120 . In the LGB group, one @entity1 (0.9%) had a nonfatal @entity1151 . This @entity1 had a history of @entity1150 . The incidence of @entity1151 was statistically higher in the superobese OGB group (P < 0.01). Despite the theoretical hindrance to venous return and vena caval compression observed with @entity516 , fewer PEs occurred in the laparoscopic group. Our data, however, suggest that @entity1 with a BMI > 55 kg/m(2) might be at an increased risk for @entity1151 independent of operative approach.

title: The incidence of XXXX in open versus laparoscopic gastric bypass.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['venous stasis disease']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity7405 :: ('MESH:D059246', 'Disease') :: ['tachypnea']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['PE', 'pulmonary embolism']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis']

entities_list: @entity516 :: ('MESH:D011027', 'Disease') :: ['pneumoperitoneum']

answer: @entity1151 :: (MESH:D011655,Disease) :: ['pulmonary embolism']


abstract: BACKGROUND: Provoked @entity2411 is a relatively common condition that affects sexual activity. Multidisciplinary care is indicated and @entity9381 injections are safe and effective treatment in this indication. AIMS: To assess the long-term efficacy of @entity9381 in provoked @entity2411 . MATERIALS AND METHODS: Twenty-one @entity1 treated with @entity9381 injections (50U in each bulbospongiosus muscle) 24 months prior to the study were included. Data on @entity158 [assessed using a visual analogue scale (VAS)], quality of life [measured by the Dermatology Life Quality Index (DLQI)] and quality of sex life [assessed using the Female Sexual Function Index (FSFI)] were collected before treatment, and 3 and 24 months after injection. RESULTS: Nineteen @entity1 participated in the study and 37% had no @entity158 after 24 months. Significant improvements were noted in the VAS, DLQI and FSFI scores between baseline and 24 months post treatment (P < 0.0001). After 24 months, 18 @entity1 (95%) were able to have sexual intercourse. This study was open and non-controlled. DISCUSSION AND CONCLUSION: 100U @entity9381 injections constitute an effective treatment in provoked @entity2411 with results maintained after 2 years. They significantly improve @entity158 , and have a positive impact on @entity1 quality of life and sex life. Beneficial effects continue in the long-term, allowing @entity1 to resume sexual activity.

title: Long-term assessment of effectiveness and quality of life of @entity9381 injections in provoked XXXX .

entities_list: @entity2411 :: ('MESH:D056650', 'Disease') :: ['vestibulodynia']

entities_list: @entity9381 :: ('MESH:C542870', 'Chemical') :: ['OnabotulinumtoxinA']

answer: @entity2411 :: (MESH:D056650,Disease) :: ['vestibulodynia']


abstract: Recurrent exacerbation in @entity12088 (EO) often warrants multidisciplinary treatment and collaboration with a dermatologist. The aim of this pilot study was to ascertain the efficacy of topical @entity1140 ointment application in chronic, non-infectious and therapy-resistant EO. In a prospective clinical study, the efficacy of @entity1140 ointment 0.1% was examined in 53 @entity1 with therapy-refractory chronic EO of confirmed non-infectious etiology. Clinical examination took place prior to treatment (V1), at the end (V2) and during follow-up investigations (V3) of 28 @entity1 over 10-22 months. @entity1 were evaluated for the symptoms @entity7867 , @entity4 , @entity2972 , @entity5105 , @entity111 and desquamation on a 6-point scale. The short-term results after topical application of @entity1140 (V2) showed a clear improvement in 85% of the @entity1 (N = 45) and significant drop in severity scores for all clinical parameters (p < 0.001). The long-term follow-up studies (V3) revealed that a one-time treatment cycle led to complete remission in 46% of @entity1 (N = 28). The remaining 54% had recurrent EO events, however, with significantly longer symptom-free intervals. Within the observation period, no relevant local or systemic side effects were observed, except for occasional skin burning, stinging, or itching. This interdisciplinary study between dermatologists and ENT specialists clearly demonstrates that the topical application of 0.1% @entity1140 ointment is an effective and well-tolerated new option in the treatment of chronic recalcitrant EO. Furthermore, it shows that dermatologists, with their experience in topical immunomodulatory therapy, can make valuable contributions to the treatment of @entity32 in other medical fields.

title: Topical XXXX treatment for chronic dermatitis of the ear.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory disorders']

entities_list: @entity111 :: ('MESH:D011537', 'Disease') :: ['pruritus']

entities_list: @entity12088 :: ('MESH:D010032', 'Disease') :: ['chronic recalcitrant external otitis']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus']

answer: @entity1140 :: (MESH:D016559,Chemical) :: ['tacrolimus']


abstract: OBJECTIVE: To review a case series of @entity1 with @entity179 presenting to a laryngologist for workup of @entity7364 and found to have bilateral vocal fold paresis. DESIGN: Case series. SETTING: Tertiary care voice center. @entity1 : Series of @entity1 with @entity179 examined for @entity7364 . MAIN OUTCOME MEASURES: History and physical examination including fiberoptic laryngoscopy were performed on all @entity1 . Some @entity1 underwent polysomnography. RESULTS: Seven @entity1 during a 2-year period were noted to have bilateral abductor vocal fold paresis. Five of 7 (71%) had the diagnosis of multiple system @entity194 proposed by the laryngologist. All 7 @entity1 described @entity25 @entity1353 with stridor. CONCLUSIONS: @entity1 with @entity179 such as @entity191 should be examined for multiple system @entity194 and for evidence of bilateral vocal fold paresis. Workup for stridor should include polysomnography. Treatment of glottic obstruction in these @entity1 includes constant positive airway pressure at night or tracheotomy. The finding of bilateral vocal fold paresis can be life threatening.

title: Bilateral vocal fold paresis and multiple system XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity1353 :: ('MESH:D004417', 'Disease') :: ['breathing']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ['Parkinson disease']

entities_list: @entity7364 :: ('MESH:D055154', 'Disease') :: ['dysphonia']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['systemic neurodegenerative disorders', 'systemic neurodegenerative disease', 'neurodegenerative disorders']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep-disordered']

answer: @entity194 :: (MESH:D001284,Disease) :: ['atrophy']


abstract: BACKGROUND: The aim of this study was to develop a valid tool for internal process analysis of @entity64 management in order to identify possible improvements. METHOD: 939 @entity64 @entity1 were classified into DRG diagnoses. Specific parameters known to influence the length of stay were analysed. Subgroup analyses were carried out in @entity1 with @entity63 regarding a) differences between the neurological sections/ wards, and b) length of stay in correlation with resident level of training and the physician staffing in the particular department/ ward over the year. RESULTS: A difference in the length of stay of 1-2 days was revealed between the neurological departments/wards. Transfer to rehabilitation centres increased the length of stay by 5 days. Length of stay correlated with the training level of residents and staffing in the department/ward. Capacity overload due to reduced staffing or high fluctuation of staff increased the length of stay significantly. CONCLUSION: @entity63 @entity1 were shown to be a homogeneous subtype of @entity64 @entity1 , who can be used as a valid tool to analyse internal processes. This analysis revealed that length of stay depends on resident level of training and workload.

title: [The XXXX ( @entity63 )--a valid instrument for intern process analyses in neurological departments].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity63 :: (MESH:D007511,Disease) :: ['transient ischemic attack']


abstract: BACKGROUND: Several studies have reported an association between @entity7160 ( @entity7160 ) or other forms of @entity5881 ( @entity5881 ) and the genetic variant @entity14894 ( @entity6993 ) in adiponutrin/ @entity14895 gene ( @entity14895 ). AIM: To evaluate the influence of this variant on @entity7160 and other forms of @entity5881 . METHODS: We performed a systematic review of previous studies on the relationship between @entity14894 of @entity14895 and @entity5881 and meta-analysis was conducted in a random-effects model. Calculations of the odds ratios (ORs) and their confidence intervals (CIs), tests for heterogeneity and sensitivity analyses were performed. RESULTS: Database search identified 11 previous studies available for inclusion with a total of 3495 @entity1 with @entity5881 (2087 with @entity7160 ) and 5038 controls (4007 healthy subjects and 1031 alcoholics without @entity5881 ). @entity1 with @entity7160 compared to controls had a significantly higher prevalence of the G allele when comparing GG vs. CC (OR 4.30, 95% CI 3.25-5.69; P < 0.00001) or GC vs. CC genotypes (GC vs. CC: OR 1.91, 95% CI 1.67-2.17) or under a recessive or dominant model. Similar results were found when comparing separately @entity1 with @entity7160 vs. alcoholics without @entity5881 or healthy subjects. An association of the G allele with @entity5881 emerged when comparing @entity5881 @entity1 vs. alcoholics without @entity5881 and/or healthy subjects although moderate to large heterogeneity was observed. Our data suggested an additive genetic model for this variant in @entity5881 . CONCLUSION: Our meta-analysis shows that the @entity14894 variant of @entity14895 is clearly associated with @entity7160 .

title: Systematic review with meta-analysis: the I148M variant of @entity14895 gene ( @entity14895 ) is significantly associated with XXXX .

entities_list: @entity5881 :: ('MESH:D008108', 'Disease') :: ['ALD', 'alcoholic liver disease']

entities_list: @entity6993 :: ('c|SUB|C||G', 'DNAMutation') :: ['C>G']

entities_list: @entity14895 :: ('80339', 'Gene') :: ['patatin-like phospholipase domain-containing 3', 'PNPLA3']

entities_list: @entity7160 :: ('MESH:D008104', 'Disease') :: ['ALC', 'alcoholic liver cirrhosis']

answer: @entity7160 :: (MESH:D008104,Disease) :: ['alcoholic liver cirrhosis']


abstract: The pathological findings in 14 cases of @entity9296 and three cases of @entity788 have been studied in relation to the clinical effects. All the @entity1 were @entity1 , and their ages ranged from 13 to 90 years. @entity5 measuring 2 to 4 cm. in diameter had not caused symptoms or signs. Tumours from 7 to 12 cm. in diameter had been felt in the upper abdomen and half the @entity1 with such @entity5 had complained of @entity158 . In two cases with large @entity5 there was severe @entity548 into the alimentary canal. THE CYSTADENOMAS WERE OF TWO TYPES: 1 Tumours with small loculi lined by cubical epithelium, in which there was little secretion of mucus by the epithelium but abundant mucoid stroma. There were six of these @entity5 and we have no evidence of malignant change in this type. 2 Tumours with relatively large cystic spaces filled with mucus and lined by tall, mucus-secreting epithelium. There were eight of these, and the possibility of malignant transformation in this type of @entity5 is indicated by the finding that in three cases of @entity7157 two appeared to have been preceded by simple mucus-secreting @entity9296 . Signs of recent or old @entity548 were common in both types of @entity9296 and also in the @entity7157 .

title: XXXX and @entity788 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['cystadenocarcinoma of the pancreas']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding', 'haemorrhage']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Four tumours', 'tumours', 'tumour']

entities_list: @entity9296 :: ('MESH:D003537', 'Disease') :: ['cystadenomas', 'cystadenoma']

entities_list: @entity7157 :: ('MESH:D003536', 'Disease') :: ['cystadenocarcinomas', 'cystadenocarcinoma']

answer: @entity9296 :: (MESH:D003537,Disease) :: ['Cystadenoma']


abstract: Thirty-one @entity1 with @entity0 either resistant to @entity4349 -based regimens or relapsing after @entity4349 -based adjuvant chemotherapy received a combination of a 3-h infusion of @entity1311 135 mg/m2 on day 1 and a 4-h infusion of @entity1260 1.7 g/m2 on days 2 to 4 of a 22-day cycle. For inclusion in the study, @entity1 had to have measurable or evaluable progressive @entity3 or @entity66 , and to have received only one prior regimen for metastatic disease; 31 @entity1 with a median age of 49 years (range: 30-69) entered the study. Nine @entity1 (29%) had lung @entity3 , while 17 (55%) had liver @entity3 , and 19 (61%) had bone @entity3 . Only seven @entity1 (23%) had lymph node @entity3 and four (13%) had skin @entity3 . A median of seven cycles of treatment was delivered. Responses were evaluated according to World Health Organization (WHO) guidelines and side effects according to National @entity5 Institute (NCI) criteria. A panel of oncologists and one radiologist reviewed all responses. At baseline, only three @entity1 (10%) were free from the adverse effects of the prior therapy; severe nonhematological @entity137 occurred in less than 8% of @entity1 . However @entity1398 grade 3-4 occurred in 88%, while only 3% had severe @entity281 . Severe @entity882 and @entity417 were rare (4% and 8%, respectively). The overall response rate was 42% (13% complete response). Median survival and progression-free survival rates after initiation of treatment were 19.3 months and 6.1 months, respectively. With an objective response rate of 42% and median survival of 19 months, the combination of @entity1311 and @entity1260 seems to offer a promising regimen with acceptable side effects in @entity0 @entity1 relapsing after @entity4349 -based adjuvant treatment or resistant to @entity4349 treatment.

title: XXXX - @entity1260 for @entity4349 -resistant @entity0 .

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['advanced breast cancer']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['local disease']

entities_list: @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide']

answer: @entity1311 :: (MESH:D017239,Chemical) :: ['Paclitaxel']


abstract: @entity957 ( @entity957 ) is a disease that strikes many worldwide, accounting for more than 145,000 @entity204 annually. This study examined the role of @entity2533 ( @entity2533 ) signalling alterations in oral @entity105 and also its influence on the disease prognosis. In presented study, we evaluated the protein-level alterations of core @entity2533 signalling members in 20 @entity5 ( @entity5 ) - @entity12120 and @entity5 samples by western blotting. Further, we analysed the association between these alterations and prognosis of @entity1697 . For statistical analyses, univariate test like Student's 't'-test to compare expression level of various genes and logrank test has been used to compare the Kaplan-Meier survival curves. The multivariate model such as Cox's proportional hazard regression was used to verify the independent influence of each variable on the survival endpoints. A gradual decrease in the expression of @entity2533 signalling members like @entity2536 , @entity1594 , @entity7382 and @entity2534 have been noted from normal to @entity16803 in @entity5 . The bio-activeforms, @entity14877 also showed a similar trend. @entity7379 protein was downregulated significantly in the @entity16803 stage itself. Thus an inverse correlation was observed between expression of @entity2533 members and @entity5 progression.Furthermore, @entity5 @entity1 showing @entity2534 downregulation exhibited poor disease-free survival (p=0.005) and poor overall survival (p=0.012).Thus, assessing the @entity2534 protein levels can serve as one of the prognostic marker for @entity5 .

title: Prognostic implication of the loss of @entity2534 expression in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1697 :: ('MESH:D009062', 'Disease') :: ['oral carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['submucous fibrosis and 87 oral cancer', 'PMDs', 'oral cancer', 'oral cancers', 'potentially malignant oral disorders']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['Oral squamous cell carcinoma', 'OSCC']

entities_list: @entity2533 :: ('7040', 'Gene') :: ['TGFb', 'Transforming Growth Factor Beta']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis']

entities_list: @entity12120 :: ('MESH:D007971', 'Disease') :: ['leukoplakia']

answer: @entity1697 :: (MESH:D009062,Disease) :: ['oral carcinoma']


abstract: @entity1146 with @entity1757 and @entity2009 ( @entity2009 ) is a complex lesion. Since the concept of primary one-stage unifocalization evolved in the 1990s, the results of surgical treatment have improved significantly. From the midline approach, most of @entity2009 are dissected in the posterior mediastinal space between the ascending aorta and the superior vena cava. Extensive dissection maximizes the length of each MAPCA, which makes direct anastomosis of native tissue feasible without use of prosthetic materials. Pulmonary blood supply is established by a systemic-pulmonary shunt. The procedure was performed in 13 @entity1 with 7.7% of hospital mortality. There was 1 late death because of @entity281 in a @entity1 with deletion of chromosome 22q11.2. Nine @entity1 underwent intracardiac repair without mortality. The ratio of right ventricular systolic pressure to the systemic pressure after intracardiac repair did not exceed 0.5, except for 1 @entity1 . Although further follow-up is necessary, midline one-stage unifocalization is considered as the standard procedure for this lesion.

title: @entity1146 with XXXX and @entity2009 : single-stage complete unifocalization.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2009 :: ('MESH:C537782', 'Disease') :: ['major aortopulmonary collaterals', 'MAPCAs']

entities_list: @entity1757 :: ('MESH:D006345', 'Disease') :: ['ventricular septal defect']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1146 :: ('MESH:D018633', 'Disease') :: ['Pulmonary atresia']

answer: @entity1757 :: (MESH:D006345,Disease) :: ['ventricular septal defect']


abstract: OBJECTIVE: To report our experience with our first 350 cases of @entity365 ( @entity365 ), specifically assessing intraoperative complications, @entity86 , and untoward effects of the procedure. METHODS: Although increased numbers of reports have documented the efficacy of the @entity365 procedure, there are minimal data about the incidence of complications and how they are managed. We performed a retrospective review of all @entity1 undergoing the @entity365 procedure over a 4-year period to report intraoperative complications ( @entity1494 and excessive @entity548 ), @entity260 (de novo urge @entity322 , @entity409 , erosion, @entity128 , urinary retention, @entity1410 formation), and incidence of reoperation either for @entity409 or for recurrent @entity322 . RESULTS: A total of 350 @entity1 were included in the study. Fifty-five percent (194) of @entity1 underwent the @entity365 procedure in conjunction with other vaginal surgery, and 45% (156) underwent the @entity365 alone. Seventy @entity1 (20%) had previous antiincontinence surgery. Intraoperative complications included 19 bladder perforations in 17 @entity1 (4.9%) and three cases of significant @entity548 (0.9%). Postoperatively, 17 @entity1 (4.9%) had @entity409 and 42 (12%) required anticholinergic therapy beyond 6 weeks. Recurrent @entity293 developed in 38 (10.9%), erosion or poor healing in three (0.9%), @entity1410 in six (1.7%), and @entity128 in three (0.9%). Twenty-eight (8%) underwent urethral dilation in the postoperative period for varied amounts of @entity409 . Of these, 82% were either improved or were cured. Six @entity1 (1.7%) underwent a takedown of the @entity365 procedure for continued @entity409 , and two of these (33%) developed recurrent @entity3142 . To date, two @entity1 (0.5%) have undergone another procedure for recurrent or persistent @entity3142 . CONCLUSION: The @entity365 procedure is efficacious for the correction of @entity3142 . Our data show that it is a safe procedure with an acceptable complication rate when performed by surgeons who have experience with retropubic and transvaginal antiincontinence procedures.

title: Complications and untoward effects of the XXXX procedure.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['incontinence']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder perforation']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['voiding dysfunction']

entities_list: @entity128 :: ('MESH:D020209', 'Disease') :: ['nerve injury']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative morbidity']

entities_list: @entity365 :: ('MESH:D014627', 'Disease') :: ['tension-free vaginal tape', 'TVT']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infections']

entities_list: @entity3142 :: ('MESH:D014550', 'Disease') :: ['stress incontinence']

answer: @entity365 :: (MESH:D014627,Disease) :: ['tension-free vaginal tape']


abstract: The study objective was to determine whether switching @entity1 from @entity1286 to transdermal @entity3575 resulted in a reduction of @entity1286 -associated side effects, and an improvement in cognitive function and @entity1 ' well being while maintaining adequate @entity158 and symptom control. Nineteen @entity1 aged 42-86 with @entity5 , maintained on @entity1286 for @entity158 and distressed as a result of @entity1286 @entity137 , were given the dose of @entity3575 corresponding to their current @entity1286 dose. @entity158 control was then maintained (mostly @entity3575 50-100 microg/h) over the 14-day study period. Throughout the study, @entity1 ' global assessment of well being (primary efficacy variable) was statistically significantly improved. @entity25 and drowsiness were significantly less of a problem. There was a trend towards improvement in attention span/concentration, and in the power and quality of concentration. Cognitive function tests also revealed a significant improvement in working (short term) and speed of memory although not in secondary (long term) memory. @entity1 did not experience @entity1833 or delusions and there was no change in levels of @entity148 or @entity308 ( @entity308 Scale). The incidence of dizziness was significantly reduced, and there was a nonsignificant decrease in number of @entity1 who suffered @entity2045 and in the severity of this condition over the 14 days. The investigator's overall impression of treatment with transdermal @entity3575 was 'fair', which was not in agreement with the positive impression expressed by @entity1 (score 74, range: 0 worst, 100 best). Further work is required to determine if the improvement in @entity1 ' well being and cognitive function is achieved in larger study populations.

title: Opioid switching from @entity1286 to transdermal XXXX for @entity137 reduction in palliative care.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Hospital Anxiety Depression', 'depression']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['terminal cancer']

entities_list: @entity2045 :: ('MESH:D009207', 'Disease') :: ['myoclonus']

entities_list: @entity1833 :: ('MESH:D006212', 'Disease') :: ['hallucinations']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

entities_list: @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['Sleepiness']

answer: @entity3575 :: (MESH:D005283,Chemical) :: ['fentanyl']


abstract: 1. The effect of muscle length on the development of @entity925 and @entity1295 has been studied. 2. Eight normal young adults performed maximal eccentric contractions of the elbow flexors. The muscles of one arm were exercised at short length, and the contralateral muscle at long length. Each contraction lasted approximately 1 s, and was repeated once every 10 s for 30 min. 3. Muscle strength and frequency-force characteristics were measured from isometric contractions before, immediately after and at 24 h intervals for the next 4 days. Muscle tenderness was assessed daily. 4. The muscle strength was reduced by approximately 10% by exercise at short length, and by 30% by exercise at long length. 5. The 20:100 ratio (force generated by stimulation at 20 Hz/force generated at 100 Hz) fell by 30% after exercise at short length and had recovered after 24 h. Exercise at long length reduced this ratio by 65% and the muscles had not fully recovered 4 days later. 6. @entity925 developed after both exercise regimens, but was slightly worse after that at long length. 7. It is concluded that there is a length-dependent component in the development of @entity158 and @entity1295 after eccentric exercise, which had previously been thought to be caused solely by high force generation.

title: Muscle @entity1295 and XXXX after eccentric contractions at long and short length.

entities_list: @entity925 :: ('MESH:D063806', 'Disease') :: ['Muscle pain', 'muscle pain']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: PURPOSE: Several non-opioid drugs have been shown to provide @entity1337 during and after surgery. We compared @entity2614 anesthesia with @entity3575 @entity1337 to @entity2614 and non-opioid drug treatment for gastric bypass surgery and recovery. METHODS: Thirty @entity28 @entity1 (body mass index > 50 kg.m(-2)) undergoing gastric bypass were randomized to receive @entity2614 anesthesia with either @entity3575 or a non-opioid regimen including @entity6058 , @entity1338 , @entity3303 , @entity3652 , @entity2399 , and @entity1667 . @entity1286 use by @entity1 -controlled @entity1337 (PCA) pump and @entity158 score measured by visual analogue scale were determined in the postanesthesia care unit (PACU) and for the first 16 hr after surgery. Sedation was evaluated in the PACU. Investigators assessing @entity1 outcomes were blinded to the study group. RESULTS: @entity3575 treated @entity1 were more sedated in the PACU compared to the non-opioid group. Non-opioid treated @entity1 required 5.2 +/- 2.6 mg.hr(-1) @entity1286 by @entity4901 during their stay in the PACU while @entity1 anesthetized with @entity3575 used 7.8 +/- 3.3 mg.hr(-1) (P < 0.05). @entity3575 and non-opioid treated @entity1 showed no difference in @entity158 score one or 16 hr after surgery. CONCLUSION: Our results show that non-opioid @entity1337 produced @entity158 relief and less sedation during recovery from gastric bypass surgery compared to @entity3575 .

title: Non-opioid XXXX improves @entity158 relief and decreases sedation after gastric bypass surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity2399 :: ('MESH:D008278', 'Chemical') :: ['magnesium sulfate']

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity3652 :: ('MESH:D007649', 'Chemical') :: ['ketamine']

entities_list: @entity6058 :: ('MESH:D020910', 'Chemical') :: ['ketorolac']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine', 'Morphine']

entities_list: @entity2614 :: ('MESH:C009250', 'Chemical') :: ['sevoflurane']

entities_list: @entity1338 :: ('MESH:D003000', 'Chemical') :: ['clonidine']

entities_list: @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl', 'Fentanyl']

answer: @entity1337 :: (MESH:D000699,Disease) :: ['analgesia']


abstract: PURPOSE: To evaluate the safety and immunogenicity of a therapeutic @entity1082 )16 DNA vaccine administered to @entity1 with @entity1799 +cervical @entity5436 (CIN)2/3. EXPERIMENTAL DESIGN: This phase I trial incorporated the standard '3+3'' dose-escalation design with an additional 6 @entity1 allocated to the maximally tolerated dose. Healthy adult @entity1 with colposcopically directed, biopsy-proven @entity1799 + CIN2/3 received 3 i.m. vaccinations (0.5, 1, or 3 mg) of a plasmid expressing a Sig-E7(detox)-heat shock protein 70 fusion protein on days 0, 28, and 56, and underwent standard therapeutic resection of the cervical squamocolumnar junction at day 105 (week 15). The safety and immunogenicity of the vaccine and histologic outcome based on resection at week 15 were assessed. RESULTS: Fifteen @entity1 were evaluable (3 each at 0.5 and 1mg, 9 at 3 mg). The vaccine was well tolerated: most adverse events were mild, transient injection-site discomfort; no dose-limiting @entity137 were observed. Although HPVE7-specific T-cell responses to E7 detected by enzyme-linked immunospot assays ( @entity379 ) were of low frequency and magnitude, detectable increases in response subsequent to vaccination were identified in subjects in the second and third cohorts. Complete histologic regression occurred in 3 of 9 (33%; 7-70% confidence interval) individuals in the highest-dose cohort. Although the difference is not significant, it is slightly higher than would be expected in an unvaccinated cohort (25%). CONCLUSIONS: This @entity1799 DNA vaccine was safe and well tolerated. Whereas it seems possible to elicit HPV-specific T-cell responses in @entity1 with established @entity75 , other factors are likely to play a role in lesion regression.

title: A phase I trial of a XXXX DNA vaccine for @entity1799 + cervical @entity5436 2/3.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['dysplastic lesions']

entities_list: @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV']

entities_list: @entity5436 :: ('MESH:D019048', 'Disease') :: ['intraepithelial neoplasia']

answer: @entity1082 :: (10566,Species) :: ['human papillomavirus']


abstract: OBJECTIVE: To assess the safety and effect of endoscopic sphincterotomy (EST) and endoscopic @entity384 (EPBD) for @entity2877 . METHODS: 328 @entity1 with @entity2877 were subjected to EST or EPBD; they included 174 @entity1 with single stone, 112 @entity1 with two stones and 42 @entity1 with three stones (one @entity1 with 20 stones). @entity1 with stones less than 10 mm in diameter underwent EPBD and those with stones larger than 11 mm in diameter underwent EST. RESULTS: EST and EPBD succeeded in 323 @entity1 (98.5%), and failed in 5. Stones in 98 @entity1 were excluded spontaneously after endoscopic therapy. 207 @entity1 were subjected to basket or balloon stone extraction. Stones in 14 @entity1 were discharged by basket lithotripsy. Four @entity1 were given wave lithotripsy. Stones in 22 of the 323 @entity1 were extracted thoroughly after 2-3 times attempts. Total complications were noted in 2.5% of the @entity1 . @entity548 from the gastrointestinal tract was seen in one @entity1 , @entity255 in 4 @entity1 , and @entity788 in 3 @entity1 . In 92 @entity1 receiving digestive tract barium X-ray examination, 86 developed no barium reflux to the baliary tract, 2 pneumobilia, 4 barium reflux to the biliary tract. CONCLUSION: EST and EPBD are relatively safe and effective in treatment of @entity2877 , and have few complications.

title: Endoscopic sphincterotomy or @entity384 for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['Hemorrhage']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['papillary balloon dilatation']

entities_list: @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']

entities_list: @entity2877 :: ('MESH:D042883', 'Disease') :: ['choledocholithiasis']

answer: @entity2877 :: (MESH:D042883,Disease) :: ['choledocholithiasis']


abstract: The dramatic decline in the risk of @entity64 is most likely secondary to a better control of risk factors, especially @entity101 . An increase in low-density lipoprotein (LDL) @entity165 or a decrease in high-density lipoprotein (HDL) @entity165 may be additional risk factors for @entity66 . In this study, we prospectively evaluated @entity1 with @entity385 (except for cardioembolic) and age-matched controls for serum @entity165 , @entity1674 , LDL @entity165 , HDL @entity165 , very low-density lipoprotein @entity165 , and apoprotein A and B. Blood levels were determined at least 8 weeks after the @entity64 or transient @entity63 attack. Between September 1989 and September 1990,59 @entity1 and 60 controls were investigated. There were no differences among total @entity165 , @entity1674 , LDL @entity165 , and apoproteins in the two groups. HDL @entity165 , however, was significantly higher in @entity1 with @entity64 . In @entity64 @entity1 , total @entity165 (p < 0.05), LDL @entity165 (p < 0.05), and @entity755 (p < 0.05) were significantly higher in female @entity1 compared to male @entity1 . This study confirms that low HDL @entity165 may be a risk factor for @entity64 . Additionally, ally, we show that @entity14822 may appear to be more significant in @entity1 .

title: Lipid profile in XXXX : A prospective study.

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'acute stroke']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['cerebrovascular diseases']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity14822 :: ('MESH:C562935', 'Disease') :: ['lipid abnormalities']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity755 :: ('338', 'Gene') :: ['apolipoprotein B']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity64 :: (MESH:D020521,Disease) :: ['acute stroke']


abstract: @entity1931 ( @entity1931 ) is commonly employed for volatile chemical analysis, it being the method of choice for occupational health and safety monitoring. @entity1931 allows for offline capture of volatiles onto a solid sorbent followed by desorption and analysis at a later time. Although @entity1931 is routinely used in conjunction with gas chromatography ( @entity1931 -GC), the assay throughput is low and requires the use of gas standards for quantification. Another technique increasingly employed for volatile chemical analysis, @entity5274 ( @entity5274 ), is capable of real-time absolute (i.e. without calibration standards) quantification of volatile chemicals present at single digit parts per billion or higher concentrations. @entity5274 is, however, normally used for online direct analysis of gas samples rather than offline collection and analysis. The goal of this study was to determine whether a combination of @entity1931 and @entity5274 could be used to quantify volatile compounds, specifically @entity11574 and @entity8336 , more rapidly than @entity1931 -GC and without the need for calibration standards. @entity5274 was able to quantify @entity11574 and @entity8336 levels within 45 s of desorption. Due to the robustness of the @entity5274 analysis in the presence of water vapour and other major components of air, the purging of tubes usually required to remove these constituents during the @entity1931 cycle was not required, therefore reducing the @entity1931 cycle time. Comparing the quantity of @entity11574 and @entity8336 applied to the @entity1931 tube with the absolute levels quantified by @entity5274 subsequent to desorption suggested a recovery of over 95% of the applied compound. We conclude that the combination of @entity1931 and @entity5274 allows more rapid and accurate quantification of @entity11574 and @entity8336 (compared with @entity1931 -GC) to be achieved without the need for calibration standards, features which may be advantageous in applications requiring rapid analysis and high throughput.

title: The combined use of thermal desorption and @entity5274 for the quantification of @entity11574 and XXXX in air.

entities_list: @entity5274 :: ('MESH:D005184', 'Disease') :: ['selected ion flow tube mass spectrometry', 'SIFT-MS']

entities_list: @entity1931 :: ('MESH:D006930', 'Disease') :: ['TD', 'Thermal desorption']

answer: @entity8336 :: (MESH:D014050,Chemical) :: ['toluene']


abstract: INTRODUCTION: Favorable outcomes in @entity34 ( @entity34 ) for @entity64 ( @entity64 ) are related to early vessel recanalization. The mobile @entity64 treatment unit (MSTU) is an on-site, prehospital, treatment team, laboratory, and CT scanner that reduces time to treatment for intravenous thrombolysis and may also shorten time to @entity34 . METHODS: Using our MSTU database, we identified @entity1 that underwent @entity34 for @entity64 . We compared the key time metrics to historical controls, which included @entity1 that underwent @entity34 at our institution six months prior to implementation of the MSTU. We further divided the controls into two groups: (1) transferred to our institution for @entity34 and (2) directly presented to our emergency room and underwent @entity34 . RESULTS: After 164 days of service, the MSTU transported 155 @entity1 of which 5 underwent @entity34 . We identified 5 historical controls that were transferred to our center for @entity34 . Substantial reduction in times including median door to initial CT (12  minute vs. 32  minute), CT to @entity34 (82  minute vs. 165  minute), and door to MSTU/primary @entity64 center departure (37  minute vs. 106  minute) were noted among the two groups. Compared to the 6 @entity1 who presented to our institution directly, the MSTU process times were also shorter. CONCLUSION: Our initial experience shows that MSTU may help in early triage and shorten the time to @entity34 for @entity64 .

title: A Mobile Stroke Treatment Unit for Field Triage of XXXX for Intraarterial Revascularization Therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['acute ischemic stroke', 'AIS', 'stroke']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['IAT', 'intraarterial therapy']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: OBJECTIVE: To determine the efficacy of topically applied @entity5418 suspension in the treatment of @entity9645 of Beh  et disease. DESIGN AND SETTING: A randomized, placebo-controlled, double-blind study at a university referral center. @entity1 : Forty @entity1 with @entity2403 were included in the study. INTERVENTION: @entity1 were given topical @entity5418 or placebo 4 times a day for 3 months and examined clinically at biweekly intervals. MAIN OUTCOMES MEASURES: For each lesion, the mean frequency, healing time, and @entity158 were evaluated during the pretreatment, treatment, and follow-up periods. No @entity1 were given any concurrent disease-specific or immunosuppressive topical and systemic drugs during the 9-month study period. RESULTS: Of the 40 @entity1 included in the study, the results in 30 @entity1 (16 @entity1 treated with @entity5418 and 14 @entity1 treated with placebo, ranging in age from 16 to 52 years [mean+/-SD age, 34.3+/-8.1 years]) were evaluable for efficacy. Treatment with @entity5418 decreased significantly the mean frequency, healing time, and @entity158 of oral ulceration and healing time and @entity158 compared with the pretreatment period. The effectiveness of @entity5418 on the frequency and healing time of oral ulceration continued during the post-treatment period. In the placebo group, no significant difference was found in measured parameters of @entity9645 except the @entity158 of the oral ulceration between the pretreatment and treatment periods. CONCLUSION: Our results showed that topical @entity5418 suspension is an easy, safe, inexpensive, and effective treatment for @entity9645 in @entity1 with Beh  et disease.

title: The use of XXXX suspension in the treatment of @entity9645 of Beh  et disease: a randomized, placebo-controlled, double-blind study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity9645 :: ('MESH:D019226', 'Disease') :: ['oral and genital ulceration']

entities_list: @entity5418 :: ('MESH:D013392', 'Chemical') :: ['sucralfate']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain of genital ulceration', 'pain']

entities_list: @entity2403 :: ('MESH:D001528', 'Disease') :: ['Behcet disease']

answer: @entity5418 :: (MESH:D013392,Chemical) :: ['sucralfate']


abstract: This study of 16 @entity1 compares treatment for @entity1412 or @entity1373 with one of three schedules of oral progestational drugs. Treatment of @entity1869 with megestrol, 80 mg daily for 6 weeks, was not satisfactory with the first 5 @entity1 . Treatment was then prolonged to 9 weeks and 4 additional @entity1 so treated. Another 7 @entity1 were treated with @entity11796 (Provera), 80 mg daily for 6 weeks. All medication was given orally. @entity1 ranged from 36 to 60 years of age with parity from 0 to 10. Endometrial biopsies were done at intervals. All but 1 had a complete remission under therapy. This @entity1 's endometrium progressed from atypica to @entity2735 . At @entity1373 with focal @entity2735 in the endometrium, @entity1870 , and cellular @entity2909 were found. Remissions persisted only in 5, the longest period being 4 years. Hysterectomy was required in 6. None developed @entity189 . @entity1 are mildly symptomatic. It is thought that continuous progestational treatment for indefinite periods may be necessary if hysterectomy is to be avoided.

title: XXXX treated by progestins.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity11796 :: ('MESH:D017258', 'Chemical') :: ['medroxyprogesterone acetate']

entities_list: @entity2735 :: ('MESH:D002278', 'Disease') :: ['carcinoma in situ']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['hysterectomy glandular hyperplasia', 'atypical hyperplasia']

entities_list: @entity1870 :: ('MESH:D062788', 'Disease') :: ['adenomyosis']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['invasive carcinoma']

entities_list: @entity1869 :: ('MESH:D004714', 'Disease') :: ['endometrial hyperplasia']

entities_list: @entity1412 :: ('MESH:D011125', 'Disease') :: ['adenomatous']

entities_list: @entity2909 :: ('MESH:D007889', 'Disease') :: ['leiomyomas']

answer: @entity1869 :: (MESH:D004714,Disease) :: ['Endometrial hyperplasia']


abstract: INTRODUCTION: Emergency department thoracotomy ( @entity341 ) may serve as the last survival chance for @entity1 who arrive at hospital in extremis. It is considered as an effective tool for improvement of traumatic @entity1 ' outcome. The present study was done with the goal of assessing the outcome of @entity1 who underwent @entity341 and its predictive factors. METHODS: In the present study, medical charts of 50 retrospective and 8 prospective cases underwent @entity341 ( @entity341 ) were reviewed during November 2011 to June 2013. Comparisons between survived and died @entity1 were performed by Mann-Whitney U test and the predictive factors of @entity341 outcome were measured using multivariate logistic regression analysis. P < 0.05 considered statistically significant. RESULTS: Fifty-eight cases of @entity341 were enrolled (86.2% male). The mean age of @entity1 was 43.27  19.85 years with the range of 18-85. The mean time duration of CPR was recorded as 37.12  12.49 minutes. Eleven cases (19%) were alive to be transported to OR (defined as ED survived). The mean time of survival in ED survived @entity1 was 223.5  450.8 hours. More than 24 hours survival rate (late survived) was 6.9% (4 cases). Only one case (1.7%) survived to discharge from hospital (mortality rate=98.3%). There were only a significant relation between ED survival and @entity13519 , GCS, CPR duration, and @entity764 (p=0.04). The results demonstrated that initial @entity13519 lower than 80 mmHg (OR=1.03, 95% CI: 1.001-1.05, p=0.04) and presence of @entity764 (OR=2.6, 95% CI: 1.75-3.16, p=0.02) were independent predictive factors of @entity341 mortality. CONCLUSION: The findings of the present study showed that the survival rate of @entity130 @entity1 underwent @entity341 was 1.7%. In addition, it was defined that falling systolic blood pressure below 80 mmHg and blunt @entity130 of chest are independent factors that along with poor outcome.

title: Outcome of XXXX Underwent Emergency Department Thoracotomy and Its Predictive Factors.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency department thoracotomy', 'EDT']

entities_list: @entity764 :: ('MESH:D013898', 'Disease') :: ['chest trauma']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: In order to simplify management of early @entity393 , our goal was to elucidate predictors of successful medical management of miscarriage with a single dose of @entity396 . In this secondary analysis of data from a multicenter randomized controlled trial, candidate biomarkers were compared between 49 @entity1 with @entity16164 who succeeded in passing their pregnancy with a single dose of @entity396 and 46 @entity1 who did not pass their pregnancy with a @entity396 single dose. We computed the precision of trophoblastic protein and hormone concentrations to discriminate between @entity1 who succeed or fail single dose @entity396 management. We also included demographic factors in our analyses. We found overlap in the concentrations of the individual markers between @entity1 who succeeded and failed single-dose @entity396 . However, @entity3566 levels >= 4000mIU/mL and ADAM-12 levels >= 2500pg/mL were independently associated with complete uterine expulsion after one dose of @entity396 in our population. A multivariable logistic model for success included non-Hispanic ethnicity and parity <2 in addition to @entity3566 >= 4000mIU/mL and ADAM-12 >= 2500pg/mL and had an area under the receiver operating characteristic (ROC) of 0.81 (95% confidence interval: 72-90%). Categorizing @entity1 with a predicted probability of >= 0.65 resulted in a sensitivity of 75.0%, specificity 77.1% and positive predictive value of 81.8%. While preliminary, our data suggest that serum biomarkers, especially when combined with demographic characteristics, may be helpful in guiding @entity1 decision-making regarding the management of @entity177 ( @entity177 ). Further study is warranted.

title: Serum biomarkers may help predict successful @entity396 management of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patient']

entities_list: @entity16164 :: ('MESH:D000030', 'Disease') :: ['missed abortion']

entities_list: @entity396 :: ('MESH:D016595', 'Chemical') :: ['misoprostol']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['EPF', 'early pregnancy failure']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['pregnancy loss']

answer: @entity177 :: (MESH:D051437,Disease) :: ['early pregnancy failure']


abstract: We have isolated a cDNA (GhWBC1) from @entity2708 ( @entity2708 ) that encodes an @entity855 -binding cassette transporter of the WBC (white/brown complex) subfamily. Members of this subfamily are half-sized transporters and are reported to mediate lipid and drug excretion in @entity1 ( @entity1 ). GhWBC1 is highly expressed in developing fiber cells, but transcripts were also detectable in other tissues except roots. The transcript level peaked in rapidly expanding fibers from 5 to 9 @entity16771 and then decreased. The GhWBC1 expression was weak in fiber cells of an li (ligon-lintless) mutant, which is defective in fiber cell elongation. These data indicate that GhWBC1 gene expression correlates with @entity2708 fiber elongation. Transient expression of enhanced green fluorescence protein-GhWBC1 fusion protein in onion (Allium cepa) epidermal cells revealed plasma membrane localization. The GhWBC1 cDNA driven by a constitutive 35S promoter was introduced into @entity958 . About 13% of the transformants produced short siliques (SSs), whereas others had normal siliques (long siliques [LSs]). In siliques of SS lines, most embryos were severely shriveled, and only several seeds per silique could be found at maturity. The transgene expression level was higher in SS lines than in LS lines. Expression of @entity6644 , the closest homolog of GhWBC1 in @entity958 , was not altered in either SS or LS transgenic plants examined. These data suggest that GhWBC1 interferes with substance translocation that is required for @entity958 seed and silique development. Characterization of @entity958 WBC members, particularly @entity6644 , will help to dissect the role of GhWBC1 in @entity2708 fiber development and elongation.

title: An XXXX -binding cassette transporter GhWBC1 from elongating @entity2708 fibers.

entities_list: @entity1 :: ('9606', 'Species') :: ['Homo sapiens', 'human']

entities_list: @entity2708 :: ('3635', 'Species') :: ['cotton', 'Gossypium hirsutum']

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis']

answer: @entity855 :: (MESH:D000255,Chemical) :: ['ATP']


abstract: The complications of @entity532 have been well documented clinically for many years; however, the specific cellular mechanisms that lead to the dysfunction of small vessels in @entity6 are unknown. Histopathological studies on @entity532 have established thickened @entity455 membrane as one of the first and foremost structural abnormalities. Evidence suggests that this fundamental structural lesion develops, at least in part, from excess accumulation of basement membrane material in the vessel walls. Several @entity455 membrane components have been identified whose expression is up-regulated in @entity6 . Enzymes responsible for the degradation of basement membrane components have also been reported to exhibit reduced activity. Strategies are being developed to regulate the abnormal accumulation of extracellular matrix (ECM) components in @entity532 . In experimental @entity6 , @entity3650 reductase inhibitors have been found to be effective in preventing @entity455 membrane thickening when applied soon after the onset of hyperhexosemia. Clinical trials have been initiated with inhibitors of protein kinase C, an enzyme that up-regulates the synthesis of ECM components in @entity6 . Currently, gene therapy strategies are also being developed to inhibit specific gene expression responsible for excess ECM synthesis in @entity6 . Recent studies in the authors' laboratory have shown the applicability and efficacy of antisense oligonucleotides toward reducing @entity455 membrane component synthesis. Several gene regulatory approaches are currently being developed to modulate and prevent @entity455 membrane component synthesis. Such strategies may help identify key events that underlie the complex developmental stages of @entity532 .

title: Role of XXXX membrane components in @entity532 .

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular basement']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['diabetic microangiopathy']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

answer: @entity455 :: (MESH:D014652,Disease) :: ['vascular basement']


abstract: Background: The variety of rendezvous (RV) procedures has recently been extended by EUS- and PTCD-guided procedures as a complementary means to conventional ERCP. We have identified indication criteria and the potential of biliary PTCD-guided vs. EUS-guided RV. Methods: Consecutive @entity1 with @entity1448 who underwent RV were included. In all, ERCP alone was unable to achieve treatment success. Indication, technical success, and outcome in PTCD- vs. EUS-guided RV were retrospectively compared to identify criteria that indicate preference of RV technique. Site of obstruction, clinical scenario ( @entity850 with @entity733 vs. no @entity733 ) and reason for previous failure of ERC were evaluated. Results: In 32 @entity1 , three different indications for RV procedures were identified: First, a one-step access to assist in failed ERCP (type 1, intra-ductal RV); second, temporary drainage for prolonged treatment of complex biliary disease (type 2, intra-ductal RV), and @entity733 with re-establishing bile outflow (type 3, intra- @entity733 RV). Indication of PTCD- vs. EUS-guided rendezvous was competitive in type 1, but exclusive in favor of PTCD in types 2 and 3. The site of @entity253 indicated the anatomic location of RV procedures. Conclusions: This classification may help to define inclusion criteria for prospective studies on biliary RV procedures. Choice of therapeutic strategy depends on the anatomic location of the @entity253 . PTCD-guided RV might improve outcome in @entity733 .

title: Identifying Indications for Percutaneous (PTC) vs. Endoscopic  Ultrasound (EUS)- Guided "Rendezvous" Procedure in XXXX and Incomplete Endoscopic  Retrograde Cholangiography (ERC).

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity1448 :: ('MESH:D002779', 'Disease') :: ['bile duct obstruction']

entities_list: @entity733 :: ('MESH:D000038', 'Disease') :: ['drainage of cholangio-abscess', 'abscess', 'cholangio-abscess']

entities_list: @entity253 :: ('MESH:D001660', 'Disease') :: ['biliary obstruction', 'biliary obstruction and the type of the biliary lesion']

answer: @entity253 :: (MESH:D001660,Disease) :: ['Biliary Obstruction']


abstract: BACKGROUND: @entity674 ( @entity674 ) are rare @entity5 , accounting for <1% of all @entity5 of the alimentary tract. @entity674 have not been previously reported in association with gastric bypass surgery. METHODS: This study is a retrospective review of 517 consecutive morbidly @entity28 @entity1 who underwent laparoscopic Roux-en-Y gastric bypass (LRYGBP) between January 2002 and August 2005. Incidental intraoperative findings of @entity356 were recorded. RESULTS: 4 @entity1 (0.8%) were noted to have @entity674 intra-operatively upon inspection of the stomach prior to partition. All @entity674 were identified along the anterior aspect of the upper third of the stomach and were removed by laparoscopic wedge excision with at least a 1 cm margin. The 4 @entity5 were <1 cm in size and all had immunohistochemical analysis positive for @entity2467 ( @entity2467 ). None of the @entity5 had determinants of malignant behavior (high mitotic rate, @entity39 or pleomorphism). CONCLUSION: We have found a 0.8% incidence of @entity1820 in our morbidly @entity28 @entity1 undergoing LRYGBP. All of these small, benign @entity5 were found incidentally in asymptomatic @entity1 . This case series underscores the need to fully assess the stomach prior to gastric pouch formation. Without the ability to grossly determine the benign or malignant behavior of @entity674 , all these @entity5 found incidentally should be resected with adequate margins.

title: Incidental finding of @entity674 ( XXXX ) during laparoscopic gastric bypass.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasms', 'tumors']

entities_list: @entity1820 :: ('MESH:D005770', 'Disease') :: ['gastric GISTs']

entities_list: @entity674 :: ('MESH:D046152', 'Disease') :: ['GISTs', 'Gastrointestinal stromal tumors']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric GIST']

answer: @entity674 :: (MESH:D046152,Disease) :: ['GISTs']


abstract: Sensitivity of neurons to @entity172 in down-regulation of @entity172 receptor alpha ( @entity7605 ) can be thought to make a sex difference in regulatory system of reproductive activities. In this study, to investigate the sex difference of expression of @entity7605 in the @entity2339 and midbrain, the number of @entity7605 immunoreactive (-ir) cells was counted in orchidectomized (OCX) and ovariectomized (OVX) @entity35 with or without treatment with @entity172 . A week after the gonadectomy, 5 @entity35 in each female and male were injected with 1mg @entity4520 (EB). The remaining 5 @entity35 in both sexes did not receive EB. The brain was fixed 24h after EB-injection and 50 microm-serial frozen sections were made. After immunohistochemical staining for @entity7605 , the number of @entity7605 -ir cells was counted in a 0.2-mm2 frame in the anteroventral periventricular nucleus (AVPvN), the ventrolateral part of the ventromedial hypothalamic nucleus (vlVMN), the arcuate nucleus (ARCN), and the lateral mesencephalic central gray (lMCG) in 2 or 3 sections. The total number of @entity7605 -ir cells was changed to a density value (number per 1mm3). As the results, in EB-treated @entity35 , the density of @entity7605 -ir cells in all regions, except the male AVPvN and male lMCG, were lower than those in untreated @entity35 of both sexes. In the vlVMN, the density of @entity7605 -ir cells in OVX @entity35 was higher than in OCX @entity35 . These results suggest that there are sex and regional differences in the mechanisms of down-regulation of @entity7605 by @entity172 in the @entity35 brain.

title: Sex and regional differences in decrease of @entity172 receptor alpha-immunoreactive cells by @entity172 in @entity35 XXXX and midbrain.

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity2339 :: ('MESH:D007029', 'Disease') :: ['hypothalamus']

entities_list: @entity4520 :: ('MESH:C074283', 'Chemical') :: ['estradiol benzoate']

answer: @entity2339 :: (MESH:D007029,Disease) :: ['hypothalamus']


abstract: @entity1582 remains incurable. Despite the pursuit of various chemotherapeutic approaches, little improvement in outcome has been made in the last 30 years. @entity2816 , @entity619 , and @entity4581 are oral, nonmyelosuppressive agents, each with reported single agent activity against @entity1582 . We evaluated a regimen of @entity4581 ( @entity4581 ), low-dose @entity2816 and @entity619 (BLT-D) in @entity1 with previously untreated or treated @entity1582 or Waldenstr  m's @entity8057 . @entity1 were initially given @entity4581 500 mg twice daily, @entity2816 50-200 mg daily, and @entity619 40 mg weekly until disease progression. Minimum response was defined as > 50% reduction in monoclonal immunoglobulin or light chain levels in serum or urine. Response, @entity137 , and survival were determined on an evaluable and/or intent-to-treat basis. Of the 50 @entity1 available for analysis, 92% remain alive and 64% remain on treatment with a median and mean duration of treatment of 7 and 8 months, respectively. Overall, 93% of evaluable @entity1 responded to BLT-D, including 13% complete remissions, 40% near complete responses, 13% major responses, and 27% partial responses. Minimal drug resistance was initially encountered. @entity2359 , although usually mild to moderate, was the primary reason for treatment discontinuation. Only four @entity1 died, including three @entity944 in @entity1 with severe @entity66 . It appears that BLT-D is a highly effective, nonmyelosuppressive regimen for @entity1582 . Caution should be exercised when using @entity2816 , alone or in combination, in @entity1 with a preexisting tendency to @entity715 , severe @entity51 .

title: BLT-D ( @entity4581 [ @entity4581 ], low-dose @entity2816 , and XXXX ) for the treatment of @entity1582 and Waldenstr  m's @entity8057 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['cardiopulmonary disease']

entities_list: @entity944 :: ('MESH:D003645', 'Disease') :: ['sudden deaths']

entities_list: @entity4581 :: ('MESH:D017291', 'Chemical') :: ['Biaxin', 'clarithromycin']

entities_list: @entity2816 :: ('MESH:D013792', 'Chemical') :: ['Thalidomide', 'thalidomide']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'myeloma', 'Multiple myeloma']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['cardiopulmonary disease, or neurologic dysfunction']

entities_list: @entity8057 :: ('MESH:D008258', 'Disease') :: ['macroglobulinemia']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thromboses']

entities_list: @entity2359 :: ('MESH:D020258', 'Disease') :: ['Neurotoxicity']

answer: @entity619 :: (MESH:D003907,Chemical) :: ['dexamethasone']


abstract: Study Type - Therapy (case series) Level of Evidence 4. What's known on the subject? and What does the study add? Active surveillance of small renal masses has traditionally been reserved for elderly @entity1 deemed unfit for surgery or ablation. There is increasing evidence showing the safety of @entity3457 in the management of small renal masses. In this retrospective study we compared outcomes for @entity1 with small renal masses managed with @entity3457 , radical nephrectomy and @entity1625 . We showed that @entity3457 was safe and appeared as effective as immediate surgery in the management of small @entity703 . OBJECTIVE:     To compare the oncological outcomes of @entity3457 ( @entity3457 ), radical nephrectomy (RN) and @entity1625 ( @entity1625 ) in the management of T1a small renal masses (SRMs). @entity1 AND METHODS:     At present @entity3457 is used in the treatment of SRMs in elderly @entity1 with multiple co-morbidities or in those who decline surgery.     We identified all @entity1 with T1a SRMs managed with RN, @entity1625 or @entity3457 .     Retrospective data were collected from @entity1 case records with survival data and cause of death cross-referenced with the Oxford Cancer Intelligence Unit. RESULTS:     A total of 202 @entity1 with 234 T1a SRMs (solid or Bosniak IV) were identified; 71 @entity1 were managed with @entity3457 , 41 with an RN and 90 by @entity1625 .     Over a median follow-up of 34 months the mean growth rate on @entity3457 was 0.21 cm/year with 53% of SRMs managed with @entity3457 showing negative or zero growth.     No statistically significant difference was observed in overall (OS) and @entity5 -specific (CSS) survival for @entity3457 , RN and @entity1625 ( @entity3457 -CSS 98.6%, @entity3457 -OS 83%; RN-CSS 92.6%, @entity3012 80.4%; @entity1625 -CSS 96.6%, @entity3012 90.0%). CONCLUSIONS:     Active surveillance of SRMs offers oncological efficacy equivalent to surgery in the short/intermediate term.     The results of this study support a multicentre prospective randomized controlled trial designed to compare the oncological efficacy of @entity3457 and surgery.

title: Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity1625 :: ('MESH:D004828', 'Disease') :: ['PN', 'partial nephrectomy']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity3457 :: ('OMIM:612348', 'Disease') :: ['active surveillance', 'AS']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal tumours']

answer: @entity1625 :: (MESH:D004828,Disease) :: ['partial nephrectomy']


abstract: Importance: @entity1538 ( @entity1538 ) is a severe @entity179 in which most of the genetic contribution remains unexplained. Objective: To assess the prevalence of pathogenic @entity4188 sequence variants in an Australian cohort of @entity1 with @entity1538 and severe @entity227 . Design, Setting, and @entity1 : For this cohort study, we recruited 160 @entity1 with @entity1538 classified as advanced (n   =   118) and nonadvanced (n   =   42) through the Australian and New Zealand Registry of @entity726 from January 1, 2007, through April 1, 2014. Eighty individuals with no evidence of @entity726 served as a control group. We defined @entity1538 as diagnosis before age 40 years and advanced @entity1538 as @entity227 in 2 of the 4 central fixation squares on a reliable visual field test result. We performed direct sequencing of the entire coding region of @entity4188 . Data analysis was performed in October 2014. Main Outcomes and Measures: Identification and characterization of @entity4188 sequence variants. Results: We identified 7 different pathogenic variants among 8 of 118 @entity1 with advanced @entity1538 (6.8%) but none among the @entity1 with nonadvanced @entity1538 . Three @entity1 were homozygous or compound heterozygous for @entity4188 pathogenic variants, which provided a likely basis for their disease. Five @entity1 were heterozygous. The allele frequency among the @entity1 with advanced @entity1538 (11 in 236 [4.7%]) was higher than among our controls (1 in 160 [0.6%]; P   =   .02; odds ratio, 7.8 [95% CI, 0.02-1.0]) or among the control population from the Exome Aggregation Consortium database (2946 of 122 960 [2.4%]; P   =   .02; odds ratio, 2.0 [95% CI, 0.3-0.9]). Individuals with @entity4188 pathogenic variants, whether heterozygous or homozygous, had worse mean (SD) deviation on visual fields (-24.5 [5.1] [95% CI, -31.8 to -17.2] vs -15.6 [10.0] [95% CI, -17.1 to -13.6] dB; F1,126   =   5.90; P   =   .02; partial   p2   =   0.05) and were younger at diagnosis (mean [SD] age, 23.1 [8.4] [95% CI, 17.2-29.1] vs 31.5 [8.0] [95% CI, 30.1-33.0] years; F1,122   =   7.18; P   =   .008;   p2   =   0.06) than @entity1 without @entity4188 pathogenic variants. Conclusions and Relevance: @entity1 with advanced @entity1538 based on @entity227 had enrichment of @entity4188 pathogenic variants and a more severe phenotype compared with unaffected controls and @entity1 with nonadvanced @entity1538 .

title: Occurrence of XXXX Mutations in Juvenile @entity1538 With @entity227 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Participants']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual field loss']

entities_list: @entity1538 :: ('MESH:D005902', 'Disease') :: ['JOAG', 'Juvenile open-angle glaucoma']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['Advanced Glaucoma', 'glaucoma']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative eye disorder']

answer: @entity4188 :: (1545,Gene) :: ['CYP1B1']


abstract: This study was carried out to assess the efficacy and tolerability of the topical application of an aqueous extract of @entity3505 (TV) in different vehicles (cream, impregnated gauzes, foam, hydrogel, and dressing gel) for the treatment of @entity3179 . Fifty @entity1 were randomized to receive one of the five investigational vehicles. Treatment was performed up to complete healing or to a maximum of 29 days. The wound size reduction from baseline was the primary efficacy variable, which was measured by means of a noninvasive laser scanner instrument for wound assessment. In all groups, apart from the foam group, a similar trend toward the reduction of the surface area was observed. The cream showed the greatest effect on the mean reduction of the lesion size. At last visit, six @entity1066 were healed: two in the cream group, three in the gauze group, and one in the dressing gel group. In the @entity1 treated with the cream, the gauzes, the hydrogel, and the dressing gel, the reduction of lesion size was 40%-50%; the reduction was smaller in the foam group. No impact in terms of age on the healing process was found. The Total Symptoms Score decreased in all groups during the study; a greater efficacy in terms of signs/symptoms was observed in the @entity1 treated with the gauzes. In the dressing gel group, one @entity1 had an infection of the wound after 3 weeks of treatment and 2 of colonization, leading to a systemic antibiotic treatment. The events were judged as nonrelated to the device used. On the basis of the results, it could be argued that the medical device may be useful in the treatment of @entity3179 .

title: Clinical evaluation of the efficacy and safety of a medical device in various forms containing @entity3505 for the treatment of XXXX - a randomized pilot study.

entities_list: @entity3505 :: ('4565', 'Species') :: ['Triticum vulgare']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3179 :: ('MESH:D014647', 'Disease') :: ['chronic venous ulcers', 'venous lower leg ulcers']

answer: @entity3179 :: (MESH:D014647,Disease) :: ['venous leg ulcers']


abstract: OBJECTIVES: @entity1 with chronic rhinosinusitis refractory to medical management undergo elective surgery. The time from initial diagnosis to surgery varies considerably. The impact of this delay on surgical success has never previously been evaluated. DESIGN: First-time @entity1 within the National Comparative Audit of Surgery for @entity1412 and @entity102 were grouped based on time to surgery: 1) Early cohort: %lt; 12 months; 2) Mid cohort: 12-60 months; and 3) Late cohort: > 60 months. Co-morbidities and preoperative CT scores were analysed for all @entity1 . MAIN OUTCOME MEASURES: The 22-item Sino-Nasal Outcome Test scores (SNOT-22) were collected at 0, 3, 12 and 60-months. Absolute and relative SNOT-22 changes from baseline were evaluated. RESULTS: Asthma and @entity566 were significantly more prevalent in the Late versus the Early and Mid-cohorts. In addition, @entity1 in the Late cohort had greater symptom burden on the SNOT-22 and more extensive preoperative radiographic disease as determined by Lund-Mackay (LM) scores. SNOT-22 scores demonstrated greater percentage improvements in the Early versus the Mid- and Late cohorts, at all time points after surgery. At 12 and 60 months after surgery, significantly more @entity1 in the Early group achieved a clinically important change in SNOT-22 scores compared with the other groups. These differences were maintained when cohorts were matched for preoperative co-morbidities. CONCLUSION: @entity1 with @entity565 and/or @entity566 are more likely to experience delayed surgical intervention versus other @entity1 . Overall, @entity1 with delayed surgery reported less improvement in SNOT-22 scores than @entity1 treated at earlier time points, regardless of co-morbid status. Delaying surgical intervention may worsen long term clinical outcomes.

title: Does time to endoscopic sinus surgery impact outcomes in @entity102 ? Prospective findings from the National Comparative Audit of Surgery for @entity1412 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity566 :: ('MESH:D006967', 'Disease') :: ['allergies']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['Chronic Rhinosinusitis']

entities_list: @entity1412 :: ('MESH:D011125', 'Disease') :: ['Nasal Polyposis']

answer: @entity102 :: (MESH:D002908,Disease) :: ['Chronic Rhinosinusitis']


abstract: We report four cases of tuberuculosis with the lymph nodes swelling in the porta hepatis. Case 1 is 52 years-old @entity1 , who was admitted to our hospital because of @entity448 . The chest X-ray film showed abnormal shadow and he was diagnosed as @entity378 by sputum examination. At the time of hospitalization, @entity1 's conjunctiva is icteric on physical examination. The serum T-Bil was 3.21 mg/dL and D-Bil was 2.54 mg/dL. The enhanced CT showed compression of the extrahepatic common bile duct which was caused by enlarged lymph nodes secondary to @entity3298 . Case 2 is 25 years-old @entity1 , who was admitted to our hospital because of low grade @entity221 and lower @entity490 . The chest X-ray film showed abnormal shadow and he was diagnosed as @entity378 by sputum examination. An enhanced CT showed the swelling of the lymph nodes in the porta hepatis. Case 3 is 21 years-old @entity1 , who visited the outpatient clinic bacause of neck lymph node swelling. And she was diagnosed as @entity3298 of the cervical lymph-nodes by the neck lymph node biopsy. The @entity1 complained of upper @entity490 during the clinical course. The enhanced CT showed the swelling of the lymph nodes in the porta hepatis. A Case 4 is 31 years-old @entity1 , who visited to outpatient clinic bacause of @entity221 . The chest X-ray film showed mediastinal @entity3329 , and he was diagnosed as @entity378 by the thoracoscopic biopsy. The enhanced abdominal CT showed lymph nodes swelling in the porta hepatis. All of lymph nodes swelling found in our four cases markedly reduced in size on abdominal enhanced CT or ultrasonography after the initiation of anti- @entity378 standard chemotherapy. Symptom of all cases got better as well. In these clinical circumstances, it was clinically important to rule out @entity706 and @entity3329 caused by @entity5 . The enhanced abdominal CT were useful for diagnosis and follow-up as @entity3298 .

title: [Four cases of the XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient', 'man']

entities_list: @entity3329 :: ('MESH:D008206', 'Disease') :: ['lymphadenopathy']

entities_list: @entity3298 :: ('MESH:D008199', 'Disease') :: ['tuberculous adenitis']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['malignant lymphoma']

entities_list: @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculous', 'tuberculosis']

answer: @entity3298 :: (MESH:D008199,Disease) :: ['tuberculous adenitis']


abstract: PURPOSE: To analyze the effectiveness of anterior pelvic plating and subsequent percutaneous sacroiliac joint screw fixation in @entity1 with unstable pelvic ring injuries. MATERIALS AND METHODS: Thirty-two @entity1 were included with twenty-one males and eleven females. The mean age was 41 years (range, 19-76). The mean follow-up period was 51 months (range, 36-73). According to AO-OTA classification, there were 11 cases of B2 injuries, 8 cases of B3 injuries, 9 cases of C1 injuries, 2 cases of @entity1605 and 2 cases of @entity130 . In the posterior lesions, there were 20 cases of sacral @entity174 and 12 cases of @entity2720 . Anterior pelvic plating and subsequent percutaneous @entity2720 were performed. RESULTS: The clinical results were 16 cases of excellent, 10 cases of good, 4 cases of moderate and 2 cases of poor functional results. The 2 cases out of 7 moderate reductions had poor functional results with residual neurologic symptoms. The radiological results were 16 cases of anatomic, 9 cases of nearly anatomic and 7 cases of moderate reduction. All @entity1 were healed except 3 cases of nonunion at the pubic ramus. The complications encountered were 3 cases of screw loosening, 2 cases of anterior plate breakage and 1 case of @entity86 . CONCLUSION: In @entity1 with unstable pelvic ring injuries, anterior pelvic plating and subsequent percutaneous sacroiliac joint screw fixation may be a useful surgical option. The radiological results and residual neurologic symptoms had effects on its functional results.

title: Anterior pelvic plating and XXXX in unstable pelvic ring injuries.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative infection']

entities_list: @entity2720 :: ('MESH:D007592', 'Disease') :: ['sacroiliac joint disruptions or dislocations', 'sacroiliac joint fixation']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['C3 injuries']

answer: @entity2720 :: (MESH:D007592,Disease) :: ['sacroiliac joint fixation']


abstract: BACKGROUND: @entity195 ( @entity195 ) is a @entity14827 that results in @entity75 . Resting-state (RS) functional magnetic resonance imaging (fMRI) techniques have been successfully applied for quantifying brain activities of both @entity195 ( @entity195 ) and @entity73 ( @entity73 ) @entity1 . Region-based approaches are widely utilized to classify @entity1 from cognitively normal subjects (CN). Nevertheless, region-based approaches have a few limitations, reproducibility owing to selection of disease-specific brain regions, and heterogeneity of brain activities during disease progression. For coping with these issues, network-based approaches have been suggested in the field of molecular bioinformatics. In comparison with individual gene-based approaches, they acquired more accurate results in diverse disease classification, and reproducibility was confirmed by replication studies. In our work, we applied a similar methodology integrating brain pathway information into pathway activity inference, and permitting classification of both @entity73 and @entity195 @entity1 based on pathway activities rather than single region activities. RESULTS: After aggregating the 59 brain pathways from literature, we estimated brain pathway activities by using exhaustive search algorithms between @entity1 and cognitively normal subjects, and identified discriminatory pathways according to disease progression. We used three different data sets and each data set consists of two different groups. Our results show that the pathway-based approach (AUC = 0.89, 0.9, 0.75) outperformed the region-based approach (AUC = 0.69, 0.8, 0.68). Also, our approach provided enhanced diagnostic power achieving higher accuracy, sensitivity, and specificity (pathway-based approach: accuracy = 83%; sensitivity = 86%; specificity = 78%, region-based approach: accuracy = 74%; sensitivity = 78%; specificity = 76%). CONCLUSIONS: We proposed a novel method inferring brain pathway activities for disease classification. Our approach shows better classification performance than region-based approach in four classification models. We expect that brain pathway-based approach would be helpful for precise classification of @entity75 , and provide new opportunities for uncovering disrupted brain pathways caused by disease. Moreover, discriminatory pathways between @entity1 and cognitively normal subjects may facilitate the interpretation of functional alterations during disease progression.

title: Inference of brain pathway activities for XXXX classification.

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain malfunctions', 'brain disorders']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['amnestic mild cognitive impairment', 'aMCI']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

entities_list: @entity14827 :: ('MESH:D020271', 'Disease') :: ['neurodegenerative and progressive disorder']

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer's disease']


abstract: BACKGROUND: @entity5513 are known to harbor mutations in the @entity5 suppressor gene, but the mechanism of the @entity5 suppressor gene action is not well understood. Identification of genes differentially expressed in normal and diseased tissues through the use of a large-scale, cDNA microarray approach may lead to increased understanding of pathways that lead to @entity5 formation. OBJECTIVE: The objectives of this study were to evaluate the gene expression profiles in @entity5513 in comparison with normal vestibular nerve tissues and to identify pathways that may be altered in @entity808 . METHODS: Total RNA was extracted from one normal vestibular nerve and seven @entity5513 . The normal vestibular nerve was from one of the seven @entity1 with small @entity5513 . Radiolabeled cDNA was synthesized and hybridized to cDNA microarray filters that contained 25,920 known genes or expressed sequence tags. Expression profiles were imaged and analyzed. Selected genes that showed three-fold or greater difference in the intensity between the normal nerve and the @entity808 were further examined by real-time polymerase chain reaction and by immunohistochemical staining. RESULTS: Forty-two genes (0.2%) were upregulated 3-fold or more in at least 5 of the 7 @entity5 when the filter images were compared with a normal adjacent vestibular nerve. Among them, osteonectin, an angiogenesis mediator, and RhoB GTPase, which is important in cell signaling, were significantly upregulated in 5 of 7 @entity5 . Among genes that were downregulated, an apoptosis-related @entity25095 gene was highly underexpressed in 6 of 7 @entity808 when compared with the normal nerve. Also, ezrin, a relative of the @entity13755 protein, was significantly downregulated in 5 of 7 @entity5 . Real-time PCR and immunohistochemistry data support the cDNA microarray findings. CONCLUSION: Our cDNA microarray analysis of @entity808 suggested several interesting and potentially important tumorigenesis pathways associated with @entity5513 formation. Further in vivo study is necessary to define the roles of these identified genes and their potential relationships with the @entity5 suppressor gene.

title: cDNA microarray analysis of XXXX .

entities_list: @entity808 :: ('MESH:D009442', 'Disease') :: ['schwannomas']

entities_list: @entity5513 :: ('MESH:D009464', 'Disease') :: ['vestibular schwannomas', 'vestibular schwannoma', 'Vestibular schwannomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neurofibromatosis type 2 tumor', 'tumors']

answer: @entity5513 :: (MESH:D009464,Disease) :: ['vestibular schwannomas']


abstract: UNASSIGNED: The a-acetolactate decarboxylase (ALDC) can reduce @entity12741 fleetly to promote mature beer. A safe strain @entity3881 WB600 for high-yield production of ALDC was constructed with the ALDC gene saald from @entity794 L3-15. @entity214 -PAGE analysis revealed that @entity794 a-acetolactate decarboxylase (SaALDC) was successfully expressed in recombinant B. siutilis strain. The enzyme SaALDC was purified using Ni-affinity chromatography and showed a maximum activity at 45    C and pH 6.0. The values of K m and V max were 17.7   M and 2.06  mM min(-1), respectively. Due to the unstable property of SaALDC at low pH conditions that needed in brewing process, site-directed mutagenesis was proposed for improving the acidic stability of SaALDC. Homology comparative modeling analysis showed that the mutation ( @entity65214 ) gave rise to the negative-electrostatic potential on the surface of protein while the numbers of @entity3884 bonds between the mutation site ( @entity45469 ) and the around residues increased. Taken together the effect of mutation @entity45469 - @entity65214 , recombinant SaALDCN43D- @entity65214 showed dramatically improved acidic stability with prolonged half-life of 3.5  h (compared to the WT of 1.5  h) at pH 4.0. In a 5-L fermenter, the recombinant @entity3881 that could over-express SaALDCN43D- @entity65214 exhibited a high yield of 135.8 U  mL(-1) of SaALDC activity, about 320 times higher comparing to 0.42 U mL(-1) of @entity794 L3-15. This work proposed a   strategy for improving the  acidic stability of SaALDC in the   @entity3881 host.

title: Improving the acidic stability of XXXX a-acetolactate decarboxylase in @entity3881 by changing basic residues to acidic residues.

entities_list: @entity3884 :: ('MESH:D006859', 'Chemical') :: ['hydrogen']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus', 'S. aureus']

entities_list: @entity45469 :: ('p|SUB|N|43|D', 'ProteinMutation') :: ['N43D']

entities_list: @entity65214 :: ('p|SUB|K|52|D', 'ProteinMutation') :: ['K52D']

entities_list: @entity3881 :: ('1423', 'Species') :: ['Bacillus subtilis', 'B. subtilis', 'B. subtilis strain']

answer: @entity794 :: (1280,Species) :: ['Staphylococcus aureus']


abstract: AIM: The purpose of the study was to determine @entity148 and @entity308 , quality of life, and their determinants in long-term survivors of malignant @entity320 . METHODS: In a state @entity5 registry a cohort of survivors of malignant @entity320 was contacted via the physician registered. Of 1302 contactable @entity1 , 689 (52.2%) completed a questionnaire including the @entity1 Health Questionnaire with generalized @entity148 (GAD-7) and @entity308 (PHQ-9) and the EORTC Quality of Life Questionnaire (EORTC QLQ 30). Based on multiple regression analysis, predictors of quality of life and distress were identified. Comparison data were assessed in two waves of representative face-to-face household surveys of the adult German population. RESULTS: An average of 8.4 (5.7 to 12.2) years after diagnosis, distress was higher in @entity1 compared to @entity1 and in middle adulthood (vs. older @entity1 ). Symptoms were higher in @entity1 than in @entity1 , and there was a decline of functioning and increase of symptoms across the age range of both genders. Compared to the general population, there were slightly increased @entity308 and @entity148 (only @entity1 ), but no impaired global quality of life. Yet, survivors evidenced functional decline and more physical symptoms. Distress and reduced quality of life were consistently predicted by lack of social support, fear of recurrence, pessimism and self-blame. Distress was increased by a family history of @entity320 , and additional mental and somatic diseases. CONCLUSION: Overall, long-term survivors have adjusted well achieving a global quality of life comparable to the general population. Yet, compromised functional dimensions, physical symptoms and distress indicate the need for integrating psychooncological screening into oncological follow-up, which might be guided by predictors such as family history or social support. Further prospective study is needed to determine the course of adaptation to the disease and corroborate the risk factors identified.

title: @entity308 , @entity148 and Quality of Life in Long-Term Survivors of XXXX : A Register-Based Cohort Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Patient', 'men']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['Malignant Melanoma']


abstract: OBJECTIVE: To present a case of the "hook effect" occurring in the @entity4090 immunoassay in a @entity1 with @entity2013 and to review this phenomenon. METHODS: We describe the clinical, biochemical, radiologic, and pathologic data of a @entity1 with a @entity2013 , in which dilution testing of serum @entity4090 levels confirmed the presence of the hook effect. We discuss the historical and mechanistic aspects of the hook effect and then review its occurrence with the @entity4090 assay. RESULTS: A 65-year-old @entity1 sought medical attention because of @entity10 , personality changes, and "bulging" eyes. Cranial magnetic resonance imaging disclosed a 10-cm-diameter, lobulated, heterogeneous, locally invasive mass in the anterior skull base and cranial fossa. Initial laboratory testing showed a @entity4090 level of 164.5 ng/mL (normal range, 1.6 to 18.8). The pathology specimen from his surgical debulking procedure was consistent with @entity2013 . Retesting of the original serum @entity4090 sample with serial dilutions revealed a @entity4090 level of 26,000 ng/mL. A postoperative diluted @entity4090 level was 22,000 ng/mL. Both @entity4090 samples demonstrated the hook effect. @entity935 agonist therapy was initiated, and the @entity4090 level and size of the @entity5 decreased substantially. The hook effect most commonly occurs when excess antigen (for example, @entity4090 ) is present during testing. Dilution testing can counteract this assay phenomenon. CONCLUSION: Clinicians should be aware of this laboratory phenomenon when evaluating large pituitary or parasellar masses. When the hook effect is suspected, dilution testing of @entity4090 samples may prevent incorrect diagnosis and unnecessary surgical intervention in @entity1 with @entity2013 .

title: "Hook effect" in XXXX : case report and review of literature.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'man']

entities_list: @entity2013 :: ('MESH:D015175', 'Disease') :: ['prolactinoma', 'prolactinomas', 'giant prolactinoma']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['Dopamine']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headaches']

answer: @entity2013 :: (MESH:D015175,Disease) :: ['prolactinomas']


abstract: It is our hypothesis that intraislet @entity1943 regulates beta cell secretion in the isolated perfused @entity1 pancreas. The present study was designed to determine the relative influence of intraislet @entity1943 on the regulation of islet amyloid polypeptide ( @entity2532 ) and insulin secretion, and to determine the effect of specific @entity1943 receptor (SSTR) agonists on beta cell secretion during immunoneutralization of endogenous @entity1943 in the isolated perfused @entity1 pancreas. Single-pass perfusion was performed in pancreata obtained from seven cadaveric organ donors using a modified Krebs medium with 3.9 mmol/L @entity413 . Sequential test periods were separated by basal periods and experiments were performed by infusion of any of the following: (1) @entity1943 monoclonal antibody (S-Ab); (2) S-Ab + @entity7931 agonist (DC32-87); or (3) S-Ab + @entity7932 agonist (DC32-92). The changes in insulin and @entity2532 secretion from basal levels during each stimulation were calculated. Infusion of S-Ab resulted in a significant increase in insulin secretion (2033 +/- 429 pmol/L; P <0.05) but not @entity2532 . In the presence of S-Ab, infusion of the @entity7931 agonist resulted in a significant inhibition of insulin secretion (-1128 +/- 457 pmol/L; P <0.05) but not @entity2532 . In the presence of S-Ab, infusion of the @entity7932 agonist had no significant effect on insulin or @entity2532 secretion. We conclude that intraislet @entity1943 inhibits insulin secretion via @entity7931 , but not @entity2532 secretion, in the isolated perfused @entity1 pancreas model and that this effect occurs via @entity7931 . These results also suggest that insulin and @entity2532 secretion are regulated by different mechanisms despite being co-localized to the beta cell.

title: Intraislet @entity1943 inhibits insulin (via a subtype-2 XXXX receptor) but not islet amyloid polypeptide secretion in the isolated perfused @entity1 pancreas.

entities_list: @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity1943 :: (MESH:D013004,Chemical) :: ['somatostatin']


abstract: Age-related loss of melanized nigral neurons reported in the British Caucasians is not observed in Asian Indian, American and French adults. In the Americans, loss of dopaminergic phenotype occurs from midlife, without @entity179 . Here, we investigated whether nigral dopaminergic neurons in Asian Indians are lost with age or undergo morphological or biochemical dysfunction. Using unbiased stereology we estimated volume, number of melanized, borderline/non-melanized (n=34, 28 gestational weeks to 80 years) and @entity669 hydroxylase (TH)- @entity18203 co-labeled neurons (n=32, 28 gestational weeks to 80 years) in substantia nigra pars compacta. We quantified @entity18203 and TH proteins by immunoblotting (n=18, 28 gestational weeks to 69 years) and apoptotic neurons by terminal deoxynucleotidyl transferase mediated @entity1977 nick end labeling (TUNEL) staining. Nuclear and soma size was estimated by morphometry. There was no age-related decline in volume, neuronal density, neuronal numbers and TH- @entity18203 co-labeled neurons. TH and @entity18203 protein expression remained stable. Lack of TUNEL-TH co-labeled cells confirmed absence of neuronal apoptosis. The neuronal size remained unaltered. Our findings of preserved nigral dopaminergic neurons suggest no age-related loss of nigral function in Asian Indians, unlike the Americans. This may explain the lower incidence of @entity191 in Asian Indians.

title: Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to lower incidence of XXXX .

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease"]

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['frank neurodegeneration']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: BACKGROUND: @entity5052 may contribute to @entity8 . We do not know whether use of treatments that lower urate reduce the progression of @entity740 ( @entity740 ) and @entity65 . We performed a systematic review and meta-analysis of @entity23 to assess the benefits and risks of treatments that lower urate in @entity1 with stages 3-5 @entity740 . METHODS: We searched MEDLINE, EMBASE, CENTRAL, Web of Science and trial registers for @entity23 ( @entity23 ) without language restriction. Two authors independently screened articles, assessed risk of bias and extracted data. Data obtained included serum @entity414 , serum @entity1011 or other estimates of glomerular filtration rate, incidence of @entity454 ( @entity454 ), systolic and diastolic blood pressure, @entity644 , @entity65 and adverse events. RESULTS: From the 5497 citations screened, 19 @entity23 enrolling 992 @entity1 met our inclusion criteria. Given significant heterogeneity in duration of follow-up and study comparators, only trials greater than 3  months comparing @entity208 and inactive control were meta-analyzed using random effects models. Pooled estimate for @entity470 was in favour of @entity208 with a mean difference (MD) of 3.2  ml/min/1.73  m(2), 95% CI 0.16-6.2  ml/min/1.73  m(2), p   =   0.039 and this was consistent with results for serum @entity1011 . Statistically significant reductions in serum @entity414 , systolic and diastolic blood pressure were found, favouring @entity208 . There were insufficient data on adverse events, incidence of @entity454 and @entity65 for analysis. CONCLUSIONS: Adequately powered @entity23 are needed to establish whether treatments that lower urate have beneficial renal and cardiovascular effects.

title: Urate lowering therapy to improve renal outcomes in XXXX with @entity740 : systematic review and meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal injury']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'ESRD']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease']

entities_list: @entity23 :: ('MESH:D007174', 'Disease') :: ['randomized controlled trials', 'RCTs']

entities_list: @entity5052 :: ('MESH:D033461', 'Disease') :: ['Hyperuricemia']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity208 :: ('MESH:D000493', 'Chemical') :: ['allopurinol']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

entities_list: @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid']

answer: @entity1 :: (9606,Species) :: ['patients']